Evidence map›Paper›PMID 33121372›Full record

Trial reportTherapeutic advances in respiratory disease

Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.

José M Marín, Luis Mateos, Juan Roldán, José M Echave-Sustaeta, Sergi Pascual-Guardia, Maria V Pardo, Beatriz Velasco, C Elaine Jones, Sally Kilbride, David A Lipson

Open access · goldAbstract readClinical Trial, Phase IIIComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

José M MarínServicio de Neumología, IISAragón, Hospital Universitario Miguel Servet, Zaragoza, Spain.ORCID 0000-0001-9096-2294
Luis MateosServicio de Neumología, Hospital de Mérida, Badajoz, Spain.
Juan RoldánServicio de Neumología, Giromed Institute, Gerona, Spain.
José M Echave-SustaetaServicio de Neumología, Hospital Universitario Quirón Salud, Madrid, Spain.
Sergi Pascual-GuardiaServicio de Neumología, Hospital del Mar-IMIM, CIBERES, UPF, BRN, Barcelona, Spain.
Maria V PardoDepartamento Médico, España, GSK, Madrid, Spain.
Beatriz VelascoDepartamento Médico, España, GSK, Madrid, Spain.
C Elaine JonesGSK, Research Triangle Park, NC, USA.
Sally KilbrideGSK, Stockley Park West, Uxbridge, Middlesex, UK.
David A LipsonGSK, Collegeville, PA, USA.
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESGlaxoSmithKline (United States) · USHospital Universitario Quirónsalud Madrid · ESInstituto de Arqueología-Mérida · ESResearch Triangle Park Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe IMPACT trial has compared the benefit in the reduction of moderate/severe exacerbations of single inhaler triple therapy (SITT) with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) MATERIALS AND

methodsIn IMPACT, a 52-week randomized, double-blind, parallel-group, multicenter study (

resultsIn the Spain cohort, the exposure-adjusted rate of on-treatment moderate/severe COPD exacerbations per year for FF/UMEC/VI was 1.31

conclusionIn the Spain cohort of the IMPACT study, patients receiving triple therapy with FF/UMEC/VI had a lower exposure-adjusted rate of exacerbations compared with FF/VI and UMEC/VI, similar to the overall population.

Indexed as

Administration, InhalationAdultAgedAged, 80 and overAndrostadienesBenzyl AlcoholsBronchodilator AgentsChlorobenzenesDisease ProgressionDouble-Blind MethodDrug CombinationsFemaleGlucocorticoidsHumansLungMaleAndrostadienesBenzyl AlcoholsBronchodilator AgentsChlorobenzenesDrug Combinationsfluticasone furoateGlucocorticoidsGSK573719Muscarinic AntagonistsQuinuclidinesvilanterolChronic obstructive pulmonary disease (COPD)glucocorticoidLABALAMArandomized clinical trialtriple therapy

Identifiers

PMID33121372
PMCPMC7607727
OpenAlexW3096804687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.